PARPi are frequently combined with androgen receptor pathway inhibitors (ARPI) as the combination improves outcomes in patients with intact HR.51 The current guideline of the American Society of Clinical Oncology recommends PARPi in metastatic castration-resistant PCa in addition to ARPI if patients are ARPI-naïve, whereas PARPi monotherapy is reserved for patients with prior ARPI exposure and HR mutation.52 Androgen deprivation remains the cornerstone of systemic treatment in advanced PCa.53 However, the optimal sequencing and combination strategies are still unclear. The gene discussed is AR; the disease is posterior cortical atrophy.